Search Results for "hansten"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for hansten. Results 51 to 60 of 433 total matches.
In Brief: Cetirizine OTC
The Medical Letter on Drugs and Therapeutics • Jan 14, 2008 (Issue 1277)
, M.D., Albert Einstein College of Medicine
CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D. Hansten ...
Cetirizine (Zyrtec, and others) and cetirizine/pseudoephedrine (Zyrtec-D) are becoming available without a prescription this month for treatment of allergic rhinitis and urticaria in adults and children. Cetirizine is the second of the second-generation H1-antihistamines to become available over the counter. Loratadine (Claritin, and others) was the first.Cetirizine has been shown to be more effective than loratadine in suppressing histamine-induced wheals in healthy volunteers (W Carey et al. Drugs Exp Clin Res 2002; 28:243), but no well-controlled clinical trials have established that any...
In Brief: Zetia and Vytorin: The ENHANCE Study
The Medical Letter on Drugs and Therapeutics • Jan 28, 2008 (Issue 1278)
CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D. Hansten,
Pharm.D., University of Washington
ADVISORY BOARD ...
An unpublished 2-year randomized study (ENHANCE) on the effect of adding ezetimibe 10 mg to simvastatin 80 mg in 720 patients with heterozygous familial hypercholesterolemia has been in the news recently. About 80% of these patients had previously been treated with statins. The primary endpoint was the change in the intima-media thickness (IMT) of the carotid artery (baseline 0.68 and 0.69 mm); the IMT increased by 0.0111 mm with ezetimibe plus simvastatin and 0.0058 mm with simvastatin 80 mg alone (p=0.29). The ezetimibe- simvastatin combination lowered LDL-C by 58% compared to 41% lowering...
In Brief: Herbal Warning
The Medical Letter on Drugs and Therapeutics • Feb 11, 2008 (Issue 1279)
CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D. Hansten,
Pharm.D.,University of Washington
ADVISORY BOARD ...
The FDA recently advised health care professionals and consumers not to use a number of dietary supplements found to contain the phosphodiesterase-5 inhibitor sildenafil (Viagra) or an analog of the drug (www.fda.gov). Although the effects of sildenafil may be noticeable (in men), the presence of other, possibly more toxic adulterants in dietary supplements may be more difficult or impossible to detect.Other drugs previously found in dietary supplements have included lovastatin (Mevacor, and others), estrogen, alprazolam (Xanax, and others), indomethacin (Indocin, and others) and warfarin...
In Brief: Genetic Test for Carbamazepine-Induced Stevens-Johnson Syndrome
The Medical Letter on Drugs and Therapeutics • Apr 21, 2008 (Issue 1284)
of
Medicine
CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D. Hansten,
Pharm.D.,University of Washington ...
Genetic Test for Carbamazepine-Induced Stevens-Johnson Syndrome Carbamazepine (Tegretol, Carbatrol, Equetro, and others), which is now used to treat not only epilepsy but also trigeminal neuralgia and manic episodes in patients with bipolar disorder,1 is a known cause of Stevens-Johnson syndrome (SJS). The incidence of carbamazepine-induced SJS in countries with mainly white populations is 1 to 6 per 10,000 new users of the drug, but Asian patients have a 10-fold higher incidence of this reaction. An association has been found between the human leukocyte antigen (HLA)-B*1502 allele and...
In Brief: A New Indication for Colesevelam (Welchol)
The Medical Letter on Drugs and Therapeutics • May 05, 2008 (Issue 1285)
INTERACTIONS: Philip D. Hansten,
Pharm.D.,University of Washington
ADVISORY BOARD:
Jules Hirsch, M.D ...
Colesevelam (Welchol - Daiichi Sankyo - Med Lett Drugs Ther 2000; 42:102), a bile-acid sequestrant used to lower LDL cholesterol, has been approved by the FDA as an adjunct to diet and exercise in the treatment of type 2 diabetes. In unpublished studies summarized in the package insert, patients with type 2 diabetes taking metformin (Glucophage, and others), a sulfonylurea or insulin (each as either monotherapy or in combination with other anti-diabetic agents) were given colesevelam 3800 mg per day or placebo; colesevelam significantly reduced glycosylated hemoglobin (A1c) by about 0.5% more...
In Brief: Measles Outbreak
The Medical Letter on Drugs and Therapeutics • Jun 02, 2008 (Issue 1287)
of
Medicine
CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D. Hansten,
Pharm.D.,University of Washington ...
The US Centers for Disease Control and Prevention (CDC) has reported that measles outbreaks have occurred in New York City, California and Arizona in 2008, and additional cases have been confirmed in Michigan, Wisconsin, Hawaii, New York State, Pennsylvania, Illinois and Virginia (CDC Health Advisory, May 1, 2008). To date, 63 of the 64 infected patients were unvaccinated, and 54 of the cases were associated with importation of the disease. Both measles infection and vaccination (2 doses at least 28 days apart, with the first dose no earlier than 12 months of age) generally provide lifelong...
Correction: Natalizumab (Tysabri) for Crohn's Disease
The Medical Letter on Drugs and Therapeutics • Jun 02, 2008 (Issue 1287)
., Albert Einstein College of
Medicine
CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D. Hansten ...
The May 5, 2008 article (Med Lett Drugs Ther 2008; 50:34) on the approval of natalizumab (Tysabri) for treatment of Crohn's disease in the "Adverse Effects" section on page 35 included the statement: "post-marketing hepatotoxicity, sometimes fatal or requiring liver transplantation, has occurred." Actually, no fatal hepatotoxicity or liver transplantation has been reported to date. The FDA warning about post-marketing hepatotoxicity with Tysabri that was the basis for our statement said: "The combination of transaminase elevations and elevated bilirubin without evidence of obstruction is...
A Reminder: Meningococcal Vaccine
The Medical Letter on Drugs and Therapeutics • Jul 28, 2008 (Issue 1291)
Einstein College of
Medicine
CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D. Hansten,
Pharm.D ...
The U.S. Advisory Committee on Immunization Practices has recommended administration of the quadrivalent conjugated polysaccharide meningococcal vaccine (Menactra – Sanofi Pasteur) to all persons 11 to 18 years old, particularly those entering high school and college freshmen living in dormitories.1,2 The peak incidence of meningococcal disease, after early childhood, occurs in the 15-19 year-old age group. The conjugate vaccine is more immunogenic than the meningococcal capsular polysaccharide vaccine (Menommune – Sanofi Pasteur).ADVERSE EFFECTS — The most common adverse reactions with...
In Brief: Exenatide (Byetta) and Pancreatitis
The Medical Letter on Drugs and Therapeutics • Sep 08, 2008 (Issue 1294)
INTERACTIONS: Philip D. Hansten,
Pharm.D., University of Washington
ADVISORY BOARD:
Jules Hirsch, M.D ...
The FDA has issued an update (August 18, 2008; www.fda.gov) on occurrences of acute pancreatitis in patients with diabetes taking exenatide (Byetta – Amylin/Lilly). The latest update, which follows an FDA Alert in October 2007, reports 6 cases of hemorrhagic or necrotizing pancreatitis with 2 deaths in patients taking the drug. Whether pancreatitis occurs more often in patients taking exenatide than in patients with diabetes not taking exenatide is not clear.1Given by subcutaneous injection, exenatide is a synthetic peptide that stimulates release of insulin from pancreatic beta cells.2 It...
Resperate for Hypertension
The Medical Letter on Drugs and Therapeutics • Jul 02, 2007 (Issue 1264)
EDITOR, DRUG INTERACTIONS: Philip D. Hansten,
Pharm.D., University of Washington
ADVISORY BOARD ...
The FDA has approved the marketing of Resperate (InterCure), a device that helps patients breathe slowly, as an adjunct for treatment of hypertension. The FDA does not require proof of effectiveness for approval of devices with minimal potential for harm, such as this one.